Cardiol Therapeutics Inc.

Toronto – September 24, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has hit its 110-patient enrollment target for the pivotal Phase III MAVERIC trial ahead of its end-of-September guidance, and will now expand recruitment to as many as 150 patients.

Blinded review shows fewer recurrences than expected in pericarditis trial

A blinded review of patients randomized 1:1 to CardiolRxTM or placebo found a lower-than-anticipated rate of pericarditis recurrence, according to Cardiol. The MAVERIC Steering Committee recommended the enrollment increase to capture enough clinical events for a statistically robust efficacy read.

President and CEO David Elsley said the company is not aware of any change in routine clinical practice that would explain the reduced recurrence rate, calling the finding encouraging.

Toronto – September 17, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has filed a preliminary short form base shelf prospectus in Canada and a corresponding Form F-10 registration statement with the U.S. SEC, enabling the life sciences company to raise up to US$150 million over a 25-month period.

Shelf filing permits future issuance of shares, debt and warrants

The filings, made under the U.S./Canada Multijurisdictional Disclosure System, would allow Cardiol to offer Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof, once a final receipt is issued and the Registration Statement becomes effective. No securities are being offered under this announcement, and the Company said there is no assurance an offering will occur.

Toronto – September 14, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.

Cardiol schedules investor session at Lotte New York Palace Hotel

The session takes place in the Louis Room on the fourth floor of the venue. A live webcast will be available under the Events & Presentations section of the company's investor website.

Company advances Phase III trial for recurrent pericarditis treatment

Cardiol's lead candidate, CardiolRx, is being evaluated in the pivotal Phase III MAVERIC trial (NCT06708299) for recurrent pericarditis, following the completed Phase II MAvERIC-Pilot study (NCT05494788). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for pericarditis, including the recurrent form of the disease.